

Treatment Resistant Depression Market - Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/TC7B7FC24476EN.html>

Date: March 2022

Pages: 60

Price: US\$ 3,250.00 (Single User License)

ID: TC7B7FC24476EN

Abstracts

Depression if untreated at an early stage may prove fatal often resulting in suicidal tendency in ailing patients. According to the statistics provided by World Health Organization (WHO), each year 800,000 people die due to suicide. It is important for physicians to perform accurate diagnosis and identify cormorbid symptoms to confirm treatment resistant depression in ailing patients.

This report contains market size and forecasts of Treatment Resistant Depression in Global, including the following market information:

Global Treatment Resistant Depression Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Treatment Resistant Depression market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Selective Serotonin Reuptake Inhibitors Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Treatment Resistant Depression include Bristol Myers Squibb Company, Eli Lilly & Company, Janssen Pharmaceutials, Inc., Mylan Pharmaceutials, Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc.,

Valeant Pharmaceuticals International and Validus Pharmaceuticals LLC and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Treatment Resistant Depression companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Treatment Resistant Depression Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Treatment Resistant Depression Market Segment Percentages, by Type, 2021 (%)

Selective Serotonin Reuptake Inhibitors

Monoamine Oxidase Inhibitors

Tricyclic Antidepressant

Esketamine Nasal Spray

Global Treatment Resistant Depression Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Treatment Resistant Depression Market Segment Percentages, by Application, 2021 (%)

Hospitals

Clinic

Others

Global Treatment Resistant Depression Market, By Region and Country, 2017-2022,
2023-2028 (\$ Millions)

Global Treatment Resistant Depression Market Segment Percentages, By Region and
Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Treatment Resistant Depression revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Treatment Resistant Depression revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Bristol Myers Squibb Company

Eli Lilly & Company

Janssen Pharmaceutcials, Inc.

Mylan Pharmaceutcials, Inc.

Novartis AG

Otsuka Pharmaceutical Co., Ltd.

Pfizer, Inc.

Valeant Pharmaceuticals International

Validus Pharmaceuticals LLC

Wyeth

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Treatment Resistant Depression Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Treatment Resistant Depression Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL TREATMENT RESISTANT DEPRESSION OVERALL MARKET SIZE

- 2.1 Global Treatment Resistant Depression Market Size: 2021 VS 2028
- 2.2 Global Treatment Resistant Depression Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Treatment Resistant Depression Players in Global Market
- 3.2 Top Global Treatment Resistant Depression Companies Ranked by Revenue
- 3.3 Global Treatment Resistant Depression Revenue by Companies
- 3.4 Top 3 and Top 5 Treatment Resistant Depression Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Treatment Resistant Depression Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Treatment Resistant Depression Players in Global Market
 - 3.6.1 List of Global Tier 1 Treatment Resistant Depression Companies
 - 3.6.2 List of Global Tier 2 and Tier 3 Treatment Resistant Depression Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Treatment Resistant Depression Market Size Markets, 2021 & 2028

4.1.2 Selective Serotonin Reuptake Inhibitors

4.1.3 Monoamine Oxidase Inhibitors

4.1.4 Tricyclic Antidepressant

4.1.5 Esketamine Nasal Spray

4.2 By Type - Global Treatment Resistant Depression Revenue & Forecasts

4.2.1 By Type - Global Treatment Resistant Depression Revenue, 2017-2022

4.2.2 By Type - Global Treatment Resistant Depression Revenue, 2023-2028

4.2.3 By Type - Global Treatment Resistant Depression Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Treatment Resistant Depression Market Size, 2021 & 2028

5.1.2 Hospitals

5.1.3 Clinic

5.1.4 Others

5.2 By Application - Global Treatment Resistant Depression Revenue & Forecasts

5.2.1 By Application - Global Treatment Resistant Depression Revenue, 2017-2022

5.2.2 By Application - Global Treatment Resistant Depression Revenue, 2023-2028

5.2.3 By Application - Global Treatment Resistant Depression Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Treatment Resistant Depression Market Size, 2021 & 2028

6.2 By Region - Global Treatment Resistant Depression Revenue & Forecasts

6.2.1 By Region - Global Treatment Resistant Depression Revenue, 2017-2022

6.2.2 By Region - Global Treatment Resistant Depression Revenue, 2023-2028

6.2.3 By Region - Global Treatment Resistant Depression Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Treatment Resistant Depression Revenue, 2017-2028

6.3.2 US Treatment Resistant Depression Market Size, 2017-2028

6.3.3 Canada Treatment Resistant Depression Market Size, 2017-2028

6.3.4 Mexico Treatment Resistant Depression Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Treatment Resistant Depression Revenue, 2017-2028

6.4.2 Germany Treatment Resistant Depression Market Size, 2017-2028

6.4.3 France Treatment Resistant Depression Market Size, 2017-2028

6.4.4 U.K. Treatment Resistant Depression Market Size, 2017-2028

6.4.5 Italy Treatment Resistant Depression Market Size, 2017-2028

6.4.6 Russia Treatment Resistant Depression Market Size, 2017-2028

6.4.7 Nordic Countries Treatment Resistant Depression Market Size, 2017-2028

6.4.8 Benelux Treatment Resistant Depression Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Treatment Resistant Depression Revenue, 2017-2028

6.5.2 China Treatment Resistant Depression Market Size, 2017-2028

6.5.3 Japan Treatment Resistant Depression Market Size, 2017-2028

6.5.4 South Korea Treatment Resistant Depression Market Size, 2017-2028

6.5.5 Southeast Asia Treatment Resistant Depression Market Size, 2017-2028

6.5.6 India Treatment Resistant Depression Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Treatment Resistant Depression Revenue, 2017-2028

6.6.2 Brazil Treatment Resistant Depression Market Size, 2017-2028

6.6.3 Argentina Treatment Resistant Depression Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Treatment Resistant Depression Revenue, 2017-2028

6.7.2 Turkey Treatment Resistant Depression Market Size, 2017-2028

6.7.3 Israel Treatment Resistant Depression Market Size, 2017-2028

6.7.4 Saudi Arabia Treatment Resistant Depression Market Size, 2017-2028

6.7.5 UAE Treatment Resistant Depression Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Bristol Myers Squibb Company

7.1.1 Bristol Myers Squibb Company Corporate Summary

7.1.2 Bristol Myers Squibb Company Business Overview

7.1.3 Bristol Myers Squibb Company Treatment Resistant Depression Major Product Offerings

7.1.4 Bristol Myers Squibb Company Treatment Resistant Depression Revenue in Global Market (2017-2022)

7.1.5 Bristol Myers Squibb Company Key News

7.2 Eli Lilly & Company

7.2.1 Eli Lilly & Company Corporate Summary

7.2.2 Eli Lilly & Company Business Overview

7.2.3 Eli Lilly & Company Treatment Resistant Depression Major Product Offerings

7.2.4 Eli Lilly & Company Treatment Resistant Depression Revenue in Global Market (2017-2022)

7.2.5 Eli Lilly & Company Key News

7.3 Janssen Pharmaceuticals, Inc.

7.3.1 Janssen Pharmaceuticals, Inc. Corporate Summary

7.3.2 Janssen Pharmaceuticals, Inc. Business Overview

7.3.3 Janssen Pharmaceuticals, Inc. Treatment Resistant Depression Major Product Offerings

7.3.4 Janssen Pharmaceuticals, Inc. Treatment Resistant Depression Revenue in Global Market (2017-2022)

7.3.5 Janssen Pharmaceuticals, Inc. Key News

7.4 Mylan Pharmaceuticals, Inc.

7.4.1 Mylan Pharmaceuticals, Inc. Corporate Summary

7.4.2 Mylan Pharmaceuticals, Inc. Business Overview

7.4.3 Mylan Pharmaceuticals, Inc. Treatment Resistant Depression Major Product Offerings

7.4.4 Mylan Pharmaceuticals, Inc. Treatment Resistant Depression Revenue in Global Market (2017-2022)

7.4.5 Mylan Pharmaceuticals, Inc. Key News

7.5 Novartis AG

7.5.1 Novartis AG Corporate Summary

7.5.2 Novartis AG Business Overview

7.5.3 Novartis AG Treatment Resistant Depression Major Product Offerings

7.5.4 Novartis AG Treatment Resistant Depression Revenue in Global Market (2017-2022)

7.5.5 Novartis AG Key News

7.6 Otsuka Pharmaceutical Co., Ltd.

7.6.1 Otsuka Pharmaceutical Co., Ltd. Corporate Summary

7.6.2 Otsuka Pharmaceutical Co., Ltd. Business Overview

7.6.3 Otsuka Pharmaceutical Co., Ltd. Treatment Resistant Depression Major Product Offerings

7.6.4 Otsuka Pharmaceutical Co., Ltd. Treatment Resistant Depression Revenue in

Global Market (2017-2022)

7.6.5 Otsuka Pharmaceutical Co., Ltd. Key News

7.7 Pfizer, Inc.

7.7.1 Pfizer, Inc. Corporate Summary

7.7.2 Pfizer, Inc. Business Overview

7.7.3 Pfizer, Inc. Treatment Resistant Depression Major Product Offerings

7.7.4 Pfizer, Inc. Treatment Resistant Depression Revenue in Global Market

(2017-2022)

7.7.5 Pfizer, Inc. Key News

7.8 Valeant Pharmaceuticals International

7.8.1 Valeant Pharmaceuticals International Corporate Summary

7.8.2 Valeant Pharmaceuticals International Business Overview

7.8.3 Valeant Pharmaceuticals International Treatment Resistant Depression Major Product Offerings

7.8.4 Valeant Pharmaceuticals International Treatment Resistant Depression Revenue in Global Market (2017-2022)

7.8.5 Valeant Pharmaceuticals International Key News

7.9 Validus Pharmaceuticals LLC

7.9.1 Validus Pharmaceuticals LLC Corporate Summary

7.9.2 Validus Pharmaceuticals LLC Business Overview

7.9.3 Validus Pharmaceuticals LLC Treatment Resistant Depression Major Product Offerings

7.9.4 Validus Pharmaceuticals LLC Treatment Resistant Depression Revenue in Global Market (2017-2022)

7.9.5 Validus Pharmaceuticals LLC Key News

7.10 Wyeth

7.10.1 Wyeth Corporate Summary

7.10.2 Wyeth Business Overview

7.10.3 Wyeth Treatment Resistant Depression Major Product Offerings

7.10.4 Wyeth Treatment Resistant Depression Revenue in Global Market (2017-2022)

7.10.5 Wyeth Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Treatment Resistant Depression Market Opportunities & Trends in Global Market

Table 2. Treatment Resistant Depression Market Drivers in Global Market

Table 3. Treatment Resistant Depression Market Restraints in Global Market

Table 4. Key Players of Treatment Resistant Depression in Global Market

Table 5. Top Treatment Resistant Depression Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Treatment Resistant Depression Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Treatment Resistant Depression Revenue Share by Companies, 2017-2022

Table 8. Global Companies Treatment Resistant Depression Product Type

Table 9. List of Global Tier 1 Treatment Resistant Depression Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Treatment Resistant Depression Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Treatment Resistant Depression Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Treatment Resistant Depression Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Treatment Resistant Depression Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Treatment Resistant Depression Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Treatment Resistant Depression Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Treatment Resistant Depression Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Treatment Resistant Depression Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Treatment Resistant Depression Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Treatment Resistant Depression Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Treatment Resistant Depression Revenue, (US\$,

Mn), 2017-2022

Table 21. By Country - North America Treatment Resistant Depression Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Treatment Resistant Depression Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Treatment Resistant Depression Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Treatment Resistant Depression Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Treatment Resistant Depression Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Treatment Resistant Depression Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Treatment Resistant Depression Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Treatment Resistant Depression Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Treatment Resistant Depression Revenue, (US\$, Mn), 2023-2028

Table 30. Bristol Myers Squibb Company Corporate Summary

Table 31. Bristol Myers Squibb Company Treatment Resistant Depression Product Offerings

Table 32. Bristol Myers Squibb Company Treatment Resistant Depression Revenue (US\$, Mn), (2017-2022)

Table 33. Eli Lilly & Company Corporate Summary

Table 34. Eli Lilly & Company Treatment Resistant Depression Product Offerings

Table 35. Eli Lilly & Company Treatment Resistant Depression Revenue (US\$, Mn), (2017-2022)

Table 36. Janssen Pharmaceuticals, Inc. Corporate Summary

Table 37. Janssen Pharmaceuticals, Inc. Treatment Resistant Depression Product Offerings

Table 38. Janssen Pharmaceuticals, Inc. Treatment Resistant Depression Revenue (US\$, Mn), (2017-2022)

Table 39. Mylan Pharmaceuticals, Inc. Corporate Summary

Table 40. Mylan Pharmaceuticals, Inc. Treatment Resistant Depression Product Offerings

Table 41. Mylan Pharmaceuticals, Inc. Treatment Resistant Depression Revenue (US\$, Mn), (2017-2022)

Table 42. Novartis AG Corporate Summary

Table 43. Novartis AG Treatment Resistant Depression Product Offerings

Table 44. Novartis AG Treatment Resistant Depression Revenue (US\$, Mn), (2017-2022)

Table 45. Otsuka Pharmaceutical Co., Ltd. Corporate Summary

Table 46. Otsuka Pharmaceutical Co., Ltd. Treatment Resistant Depression Product Offerings

Table 47. Otsuka Pharmaceutical Co., Ltd. Treatment Resistant Depression Revenue (US\$, Mn), (2017-2022)

Table 48. Pfizer, Inc. Corporate Summary

Table 49. Pfizer, Inc. Treatment Resistant Depression Product Offerings

Table 50. Pfizer, Inc. Treatment Resistant Depression Revenue (US\$, Mn), (2017-2022)

Table 51. Valeant Pharmaceuticals International Corporate Summary

Table 52. Valeant Pharmaceuticals International Treatment Resistant Depression Product Offerings

Table 53. Valeant Pharmaceuticals International Treatment Resistant Depression Revenue (US\$, Mn), (2017-2022)

Table 54. Validus Pharmaceuticals LLC Corporate Summary

Table 55. Validus Pharmaceuticals LLC Treatment Resistant Depression Product Offerings

Table 56. Validus Pharmaceuticals LLC Treatment Resistant Depression Revenue (US\$, Mn), (2017-2022)

Table 57. Wyeth Corporate Summary

Table 58. Wyeth Treatment Resistant Depression Product Offerings

Table 59. Wyeth Treatment Resistant Depression Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Treatment Resistant Depression Segment by Type in 2021

Figure 2. Treatment Resistant Depression Segment by Application in 2021

Figure 3. Global Treatment Resistant Depression Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Treatment Resistant Depression Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global Treatment Resistant Depression Revenue, 2017-2028 (US\$, Mn)

Figure 7. The Top 3 and 5 Players Market Share by Treatment Resistant Depression Revenue in 2021

Figure 8. By Type - Global Treatment Resistant Depression Revenue Market Share, 2017-2028

Figure 9. By Application - Global Treatment Resistant Depression Revenue Market Share, 2017-2028

Figure 10. By Region - Global Treatment Resistant Depression Revenue Market Share, 2017-2028

Figure 11. By Country - North America Treatment Resistant Depression Revenue Market Share, 2017-2028

Figure 12. US Treatment Resistant Depression Revenue, (US\$, Mn), 2017-2028

Figure 13. Canada Treatment Resistant Depression Revenue, (US\$, Mn), 2017-2028

Figure 14. Mexico Treatment Resistant Depression Revenue, (US\$, Mn), 2017-2028

Figure 15. By Country - Europe Treatment Resistant Depression Revenue Market Share, 2017-2028

Figure 16. Germany Treatment Resistant Depression Revenue, (US\$, Mn), 2017-2028

Figure 17. France Treatment Resistant Depression Revenue, (US\$, Mn), 2017-2028

Figure 18. U.K. Treatment Resistant Depression Revenue, (US\$, Mn), 2017-2028

Figure 19. Italy Treatment Resistant Depression Revenue, (US\$, Mn), 2017-2028

Figure 20. Russia Treatment Resistant Depression Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Treatment Resistant Depression Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Treatment Resistant Depression Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Treatment Resistant Depression Revenue Market Share, 2017-2028

Figure 24. China Treatment Resistant Depression Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Treatment Resistant Depression Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Treatment Resistant Depression Revenue, (US\$, Mn),

2017-2028

Figure 27. Southeast Asia Treatment Resistant Depression Revenue, (US\$, Mn), 2017-2028

Figure 28. India Treatment Resistant Depression Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Treatment Resistant Depression Revenue Market Share, 2017-2028

Figure 30. Brazil Treatment Resistant Depression Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Treatment Resistant Depression Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Treatment Resistant Depression Revenue Market Share, 2017-2028

Figure 33. Turkey Treatment Resistant Depression Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Treatment Resistant Depression Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Treatment Resistant Depression Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Treatment Resistant Depression Revenue, (US\$, Mn), 2017-2028

Figure 37. Bristol Myers Squibb Company Treatment Resistant Depression Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Eli Lilly & Company Treatment Resistant Depression Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Janssen Pharmaceuticals, Inc. Treatment Resistant Depression Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Mylan Pharmaceuticals, Inc. Treatment Resistant Depression Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Novartis AG Treatment Resistant Depression Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Otsuka Pharmaceutical Co., Ltd. Treatment Resistant Depression Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Pfizer, Inc. Treatment Resistant Depression Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Valeant Pharmaceuticals International Treatment Resistant Depression Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Validus Pharmaceuticals LLC Treatment Resistant Depression Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Wyeth Treatment Resistant Depression Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Treatment Resistant Depression Market - Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/TC7B7FC24476EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TC7B7FC24476EN.html>